In January 2016, the Metastatic Breast Cancer Alliance (the Alliance) convened a think tank of stakeholders from academia, government, industry, and patient advocacy to discuss gaps and opportunities in clinical and translational research in metastatic breast cancer.
The American Society of Clinical Oncology (ASCO) is hosting more than 35,000 cancer researchers, doctors, patient advocates and industry representatives from around the world in Chicago for their 55th annual meeting. Much anticipated new data is being presented relevant to breast cancer, and particularly, metastatic breast cancer.
More than 150,000, new study shows. The number of women living with MBC is increasing. The lack of robust epidemiological statistics on the number of people living with metastatic breast cancer (MBC) was highlighted as one of many critical gaps to making advances for MBC in our Landscape Report.
Moonshots and Metastatic Disease One topic that arose on the MBC Alliance Research Task Force as the Alliance moved from conducting the Landscape Analysis to actionable projects to advance research was a series of discussions on the need for more research to be conducted on patients with an exceptionally long response, or unusually poor response to therapy,
With the expert help of author and journalist Sunny Sea Gold, the “story” of the beginnings of the Alliance is now available for distribution. Including interviews with and case studies of some of our founding members, Gold has crafted an article that we hope will increase awareness of the Alliance and its work while also